BTCC / BTCC Square / Global Cryptocurrency /
Protagonist Therapeutics (PTGX) Surges 30% on JNJ Acquisition Talks

Protagonist Therapeutics (PTGX) Surges 30% on JNJ Acquisition Talks

Published:
2025-10-10 17:51:02
20
3
BTCCSquare news:

Shares of Protagonist Therapeutics (PTGX) soared over 30% following reports of ongoing acquisition talks with healthcare giant Johnson & Johnson (JNJ). Trading was temporarily halted due to intense investor interest, despite no specific deal terms being disclosed.

The potential merger WOULD strengthen an existing partnership focused on Icotrokinra, a once-daily treatment for ulcerative colitis. Recent Phase IIb trial data showed 30.2% clinical remission rates, significantly outperforming the placebo group's 11.1%. The drug now advances to Phase III trials.

|Square

Get the BTCC app to start your crypto journey

Get started today Scan to join our 100M+ users